Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 920 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Study Shows Music Eases Pain and Other Symptoms for Patients Undergoing... June 6, 2019 Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas July 10, 2023 Steroids May Limit the Effectiveness of Immunotherapy for Brain Cancer December 28, 2020 Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated... October 24, 2025 Load more HOT NEWS Husband Turns Wife’s Inspiring Poem for Her Daughters into a Book... What to Expect During a Skin Cancer Screening ESMO Targeted Anticancer Therapies Congress 2021, 1-2 March Adjuvant Capecitabine-Containing Regimen Improves Modestly Overall Survival in Patients with Early...
